Sun Pharmaceutical launches generic versions of Daiichi Sankyo medicines in US market

Indian multinational pharmaceutical major Sun Pharmaceutical Industries on Thursday launched generic versions of Daiichi Sankyo medicines in the US market which helps in treating high blood pressure.

In a BSE filing, Sun Pharmaceutical Industries said "its wholly owned subsidiary has launched in US, the authorized generic versions for all strengths of Benicar, Benicar HCT, Azor and Tribenzor of Daiichi Sankyo Inc".

Four medicines include Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide, Amlodipine Besylate-Olmesartan Medoxomil and Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets.

"The launch is pursuant to a distribution and supply agreement between Sun Pharma's wholly owned subsidiary and Daiichi Sankyo Inc, which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period," it added. Shares of Sun Pharma were trading at Rs 745.05 apiece on the BSE, up 0.74 per cent from the previous close.